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Abstract
Background: TNFa inhibitor therapy has greatly improved the treatment of patients with rheumatoid arthritis, however at
least 30% do not respond. We aimed to investigate insertions and deletions (INDELS) associated with response to TNFa
inhibitors in patients with rheumatoid arthritis (RA).
Methodology and Principal Findings: In the DANBIO Registry we identified 237 TNFa inhibitor naı ¨ve patients with RA (81%
women; median age 56 years; disease duration 6 years) who initiated treatment with infliximab (n=160), adalimumab
(n=56) or etanercept (n=21) between 1999 and 2008 according to national treatment guidelines. Clinical response was
assessed at week 26 using EULAR response criteria. Based on literature, we selected 213 INDELS potentially related to RA
and treatment response using the GeneVaH (Compugen) in silico database of 350,000 genetic variations in the human
genome. Genomic segments were amplified by polymerase chain reaction (PCR), and genotyped by Sanger sequencing or
fragment analysis. We tested the association between genotypes and EULAR good response versus no response, and EULAR
good response versus moderate/no response using Fisher’s exact test. At baseline the median DAS28 was 5.1. At week 26,
68 (29%) patients were EULAR good responders, while 81 (34%) and 88 (37%) patients were moderate and non-responders,
respectively. A 19 base pair insertion within the CD6 gene was associated with EULAR good response vs. no response
(OR=4.43, 95% CI: 1.99–10.09, p=7.211610
25) and with EULAR good response vs. moderate/no response (OR=4.54, 95%
CI: 2.29–8.99, p=3.336610
26). A microsatellite within the syntaxin binding protein 6 (STXBP6) was associated with EULAR
good response vs. no response (OR=4.01, 95% CI: 1.92–8.49, p=5.067610
25).
Conclusion: Genetic variations within CD6 and STXBP6 may influence response to TNFa inhibitors in patients with RA.
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Introduction
Tumor necrosis factor alpha (TNFa) inhibitor therapy has
greatly improved outcome in patients with moderate and severe
rheumatoid arthritis (RA) [1–3]. Unfortunately, drug response is
variable and approximately 30% of patients with RA do not
respond to TNFa inhibitors or fail to maintain initial response [1–
4]. Early and aggressive treatment is essential to suppress
inflammation and progression of joint destructions, and as the
number of biologic therapies increases, there is a growing need for
predictive biomarkers of drug response in patients with RA [5,6].
Clinical and serological predictors of treatment response such as
concomitant methotrexate therapy, functional disability, gender,
smoking status, IgM-rheumatoid factor (RF) and antibodies
against citrullinated peptides (ACPA) are likely to influence
response to TNFa inhibitors. However neither clinical nor
serological biomarkers have shown to be useful as predictive
biomarkers of response to TNFa inhibitors at the individual level
in clinical practice [4,7,8].
Since the completion of the Human HapMap Project, there has
been a burst in the number of pharmacogenetic studies aiming to
identify genetic variation associated with response to TNFa
inhibitors in patients with RA. The main focus has been on RA
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TNF gene itself and genes implicated in the TNFa signaling
pathway [8–21]. Recently, two genome-wide association studies
(GWASs) investigated the association of hundreds of single
nucleotide polymorphisms (SNPs) and response to TNFa inhib-
itors [22,23]. So far, several genetic biomarkers with suggestive
association have been identified, but results are contradictory or
need to be validated.
During the last decade, millions of insertions and deletions
(INDELS) have been discovered in human populations and
personal genomes. INDELS are structural variations of DNA,
owing to deletions or insertions ranging from 1 to 10,000 base pair
(bp) in length. Many of these INDELS map to functionally
important sites within human genes, and are likely to contribute to
phenotypic diversity and diseases including inflammatory diseases
such as RA [24,25]. It is unknown whether INDELS influence
treatment response to TNFa inhibitors in patients with RA. The
aim of the present study was to investigate the association between
INDELS and response to TNFa inhibitors in patients with RA
treated in routine care.
Materials and Methods
Patients
Based on the DANBIO registry, we identified 237 patients with
RA (the Copenhagen Cohort) initiating therapy with TNFa
inhibitors between October 1999 and August 2008 at five
departments of Rheumatology in the area of Copenhagen,
Denmark (Hvidovre Hospital (n=212), Herlev Hospital (n=13),
Rigshospitalet (n=7), Bispebjerg Hospital (n=1), and Gentofte
Hospital (n=4)). The DANBIO registry is a nationwide registry
that prospectively collects clinical data on all Danish patients with
inflammatory rheumatic joint diseases [26]. Patients were included
in the study if they had RA according to the ACR 1987 criteria
[27] and had available DNA samples drawn before start of TNFa
inhibitor treatment. All patients were naı ¨ve to biologic treatment
and initiated treatment with TNFa inhibitors (infliximab (n=160),
adalimumab (n=56), and etanercept (n=21)) according to the
Danish national guidelines. They had high disease activity and/or
progressive radiographical structural joint damage despite treat-
ment with at least two different disease-modifying anti-rheumatic
drugs (DMARDs) including methotrexate (MTX). Clinical assess-
ments at the start of treatment (baseline) and at week 26 were
included in the present study. Clinical evaluation included tender
and swollen joint counts (28 joints), visual analogue scales (VAS)
scores of pain, patient global and physician global, health
assessment questionnaire (HAQ), serum C-reactive protein
(CRP), and 28-joint count Disease Activity Score (DAS28) based
on 4 variables (the number of swollen and tender joints, patient
global score and CRP) [28]. Treatment response was calculated at
week 26 using EULAR (European League Against Rheumatism)
response criteria [29]. Blood samples for DNA extraction were
drawn at baseline and stored at minus 80 degree Celsius.
Ethics Statement
The study was performed according to the Declaration of
Helsinki. Forty-seven patients were also participants in an imaging
study [30]. The study was approved by the the Ethical Committee
of the Capital Region (Copenhagen), Denmark (H-KH-298094).
All patients gave written informed consent to store blood samples
in a research biobank for future studies. Written informed consent
regarding the use of blood for genetic analysis was waived by the
Ethical Committee of the Capital Region (Copenhagen). Accord-
ing to the Danish Health Act, the committee may grant exemption
from the requirement of consent if a notifiable database research
project does not involve any health risks and if under the given
conditions the research project cannot otherwise put a strain on
the trial subject. This also applies if it would be impossible or
disproportionately difficult to obtain informed consent.
Marker Selection and Genotyping
We selected genes related to RA and TNFa inhibitor treatment.
This included the receptors for TNF and their downstream
pathways, genes associated with treatment response in previously
published pharmacogenomic studies of patients with RA treated
with TNFa inhibitors, genes that were over-expressed in
previously published expression studies of patients with RA treated
with TNFa inhibitors, RA susceptibility genes, and serological
biomarkers for RA. Using the GeneVaH platform (Compugen,
Tel-Aviv, Israel), 213 INDELS were chosen according to their
confidence level of prediction, the potential effect of the INDEL
on the gene and the relevance of the gene. The GeneVa platform
incorporates an in silico database of approximately 350,000
predicted non-SNP genetic variations, up to a length of 500 bp,
in the human genome. DNA was amplified using polymerase
chain reaction (PCR). One hundred and twenty-two amplicons
were genotyped using sequencing and 91 were genotyped using
fragment analysis. When using sequencing, the two genomic
copies of the amplicon were sequenced together and separated
computationally. SNPs and 1–2 bp INDELS were ignored. Some
alleles were grouped together since they could not be reliably
separated, for example if the amplicon was long and the
sequencing quality became too low. Fragment analysis was used
in cases where sequencing could not be applied, usually in the
presence of long 1- or 2 bp repeats. The length measurements
were up to 1–2 bp, and alleles were grouped together so that there
was a minimum difference of 4 bp between groups.
Statistics
In order to maximize the probability of discovering a response
marker we chose to compare the genotypes of EULAR good
responders and non-responders, excluding the moderate response
group in the initial analysis. In a secondary analysis, the patients
with moderate response were added to either the group of good
responders or non-responders in order to increase the size of the
cohort. The alleles of each amplicon were divided into two groups,
and either the dominant or the recessive model for these groups
was used. There were two types of allele grouping: all alleles with
length smaller or larger than some threshold, or one allele vs. all
others. For bi-allelic amplicons there is only one allele grouping
possible, one allele vs. the other. There are two tests possible in this
case since the recessive and dominant models for one allele are the
same as the dominant and recessive models for the other allele,
respectively. For multi-allelic amplicons more tests are possible.
Only tests for which the minimal genotype group size was at least
10% of the total number of samples with genotypes for this
amplicon were considered. The associations between genotypes
and EULAR good response versus no response, EULAR good/
moderate versus no response, and EULAR good versus moderate/
no response were calculated using Fisher’s exact test.
Bonferroni corrections were performed to account for multiple
testing. If Nmarker is the number of amplicons with at least one test
possible, and Ntest is the number of tests for a specific amplicon,
then the type I error threshold for any test of a certain amplicon
was set at 0.05/(Nmarker6Ntest). Statistical analysis was performed
using R, version 2.6.0 (http://www.R-project.org).
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Baseline characteristics of the 237 patients are shown in Table 1.
Median age at inclusion was 56 years, 81% were females, 66%
were IgM-RF positive and 57% were anti-cyclic citrullinated
protein antibody (anti-CCP) positive. The median DAS28 at
baseline was 5.1. A total of 68% initiated treatment with
infliximab, 23% with adalimumab, and 9% with etanercept.
Eighty-seven % received concomitant MTX treatment. After
26 weeks of treatment, 29% of the patients were classified as good
responders, 34% as moderate responders and 37% as non
responders according to the EULAR response criteria.
A total of 213 amplicons were tested. Detailed information
regarding the tested amplicons including number of alleles for
each amplicon, number of tests when comparing good responders
and non-responders, length difference between longest and
shortest allele, rate (%) of the samples that were successfully
genotyped, Hardy-Weinberg equilibrium, and p-values (Fisher’s
exact test) comparing good responders to non-responders is listed
in Table S1. Two amplicons failed genotyping and another
amplicon turned out to be non-variable. In 19 of the tested
amplicons, at least 5% of the samples had no genotype (rate
,95%), and in 5 of these amplicons at least 10% of the samples
had no genotype (rate ,90%). The lowest genotyping rate for an
amplicon was 72%. Missing genotypes could be the result of an
unanticipated SNP in one of the primers. No correlation between
genotyping rates and genomic location was observed. Seventy-one
bi-allelic amplicons and 139 multi-allelic amplicons were identi-
fied. There were 202 amplicons for which Ntest was at least one;
hence the number of markers (Nmarker) was 202. Two amplicons
had a p-value less than the significance threshold. One was the bi-
allelic CGEN-40002 and the other was the multi-allelic CGEN-
40003.
Patients with Good or no EULAR Response
CGEN-40002. The bi-allelic CGEN-40002 amplicon repre-
sents a 19 bp insertion within the CD6 gene on chromosome 11.
The lengths of the alleles are 493 and 512 bp respectively. Forty-
five patients out of 156 (29%) with either EULAR good response
or EULAR no response were positive for the 512 allele. Imposing
a 10% group size condition in which each genotype group
consisted of a minimum of 10% of all the patients, only one test
was possible (the existence of the long 512 allele), and the
significance threshold was then 0.05/(20261) =2.475610
24.
Patients with the 512 allele were more likely to achieve a EULAR
good response than no response (Odds ratio (OR) =4.43,
Table 1. Demographic and clinical characteristics at baseline.
Variable
All
(n=237)
Good responders
(n=68)
Moderate responders
(n=81)
Non-responders
(n=88)
Demographics
Age, years 56 (19–86) 56 (19–85) 56 (22–86) 56 (19–83)
Women 191 (81%) 56 (82%) 66 (81%) 69 (78%)
Disease duration 6 (0–56) 9 (0–47) 4 (0–47) 6 (0–56)
Ever smokers
# 145 (61%) 39 (57%) 54 (68%) 52 (60%)
Laboratory values
IgM-RF positive 157 (66%) 46 (68%) 59 (73%) 52 (59%)
Anti-CCP positive
## 70 (57%) 16 (50%) 33 (65%) 21 (54%)
CRP, mg/L 12 (2–280) 16 (4–176) 12 (4–280) 9 (2–134)
Disease activity
measures
HAQ score (0–3) 1.250 (0–3) 1.125 (0–2.750) 1.250 (0–3) 1.250 (0–2.750)
Pain score (0–100) 57 (2–100) 56.5 (6–97) 62 (8–100) 53 (2–100)
Patient Global score
(0–100)
60 (0–100) 52 (13–100) 64 (5–100) 54 (0–100)
Physician’s global
score (0–100)
48 (0–100) 43.5 (5–100) 51.5 (3–94) 44 (0–95)
DAS28 5.1 (1.6–8.2) 4.9 (3.1–7.4) 5.6 (2.4–8.2) 4.6 (1.6–7.6)
Treatment
Anti TNF drug
Infliximab 160 (68%) 43 (63%) 52 (64%) 65 (74%)
Etanercept 21 (9%) 5 (7%) 11 (14%) 5 (6%)
Adalimumab 56 (23%) 20 (30%) 18 (22%) 18 (20%)
Glucocorticoids 66 (28%) 19 (28%) 24 (30%) 23 (26%)
Methotrexate 193 (81%) 56 (82%) 67 (83%) 70 (80%)
Methotrexate dose,
mg/week
20 (0–25) 22.5 (0–25) 20 (0–25) 20 (0–25)
Values are given as median (range) or number (percentage of total).
#3 patients had missing smoking status.
##115 patients had missing anti-CCP values.
doi:10.1371/journal.pone.0038539.t001
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25), Table 2. The power was 59% using the
significance threshold of 2.475610
24 and 10,000 simulations.
CGEN-40003. CGEN-40003 represents a multi-allelic am-
plicon located within the syntaxin binding protein 6 (STXBP6)
gene on chromosome 14. It has seven alleles ranging in lengths
between 252 and 294 bp. The distribution of genotype within
the 156 patients with either EULAR good response or EULAR
no response is shown in Table 3. Imposing the 10% group size
condition, 8 tests were possible (Ntest=8), Table 4. Assuming
independence of the 8 tests, the significance threshold was 0.05/
(20268) =3.094610
25. Test #2 achieved the best result,
shown in Table 2. Patients with two alleles #280 bp were more
likely to achieve a EULAR good response than no response
(OR =4.01, p=5.067610
25) compared to patients with one or
two alleles .280 bp. The p-value for this test was higher than
the significance threshold. However, the eight tests are not
independent. Inspection showed that tests #4 and #6 are
identical and tests #1 and #5 are almost identical. Therefore,
we performed a simulation to assess the actual probability to get
such a p-value as a best result of these 8 tests. In each round
the response parameter was randomly permuted between the
samples and the tests were performed recording the minimal p-
value attained. After 600,000 rounds there were 83 results lower
than or equal to 5.067610
25, corresponding to an effective Ntest
of 2.73 (=[83/600000]/5.067610
25). The adjusted significance
threshold was then 0.05/(20262.73) =9.067610
25, larger than
the p-value. The power was 55% using the adjusted significance
threshold and 10,000 simulations.
Patients with Good, Moderate or no EULAR Response
In the secondary analysis, patients with EULAR moderate
response at week 26 were added to the analysis to increase the
number of patients and hence the power to identify INDELS
associated with response to TNFa inhibitors. When adding the
moderate responders to the non-responders, only CGEN-40002
was associated with response. No amplicons, including CGEN-
40003 and CGEN-40002, were associated with response when
good responders were combined with moderate responders.
For patients with moderate response, the distribution of the
CGEN-40002 alleles was very similar to patients with no response.
Sixty-seven patients did not have the 512 allele and 12 patients
were either heterozygote or homozygote for the 512 allele (two
patients had no genotype available). Patients positive for the 512
allele were more likely to achieve a EULAR good response than
Table 2. Association between genotype and EULAR good response versus EULAR no response.
Good EULAR
response (n=68)
No EULAR
response (n=68)
Significance
threshold*** p-value
Odds
Ratio
CGEN-40002
Allele 512
negative 37 74 2.475610
24 7.211610
25 4.43*
Allele 512
positive 31 14
CGEN-40003
Both alleles #280 50 36 9.067610
25 5.067610
25# 4.01**
One allele.280 18 52
*Odds ratio for EULAR good response being 512 positive; #adjusted p-value;
**Odds ratio for EULAR good response when both alleles are #280;
***after correction for dependency.
doi:10.1371/journal.pone.0038539.t002
Table 3. Genotype distribution of the CGEN-40003 amplicon
in patients with EULAR good or no response.
Genotype
Patients with EULAR good
or no response
(n=156)*
252/252 0
252/271 1
252/275 0
252/280 0
252/284 0
252/288 0
252/294 0
271/271 79
271/275 0
271/280 4
271/284 19
271/288 33
271/294 3
275/275 0
275/280 1
275/284 1
275/288 2
275/294 1
280/280 1
280/284 0
280/288 4
280/294 0
284/284 1
284/288 3
284/294 0
288/288 3
288/294 0
294/294 0
*Values are numbers.
doi:10.1371/journal.pone.0038539.t003
Response to TNFa Inhibitors in Rheumatoid Arthritis
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38539moderate/no response compared to patients negative for the 512
allele (OR=4.54, p=3.336610
26), Table 5. If Ntest=3 (no
moderates added, moderates added to good response, moderates
added to no response), the significance threshold was 8.251610
25,
and the power was 74.5% after 10,000 simulations.
Figure 1 shows the distribution of the CGEN-40003 alleles
according to EULAR response. Patients with the longest CGEN-
40003 alleles were more often classified as non- and moderate
responders. To investigate the relationship between allele distri-
bution and EULAR response, we compared the maximal allele
length with change in DAS28 scores after 26 weeks of treatment
(delta DAS). The Spearman rank correlation and the Pearson
correlation were approximately 20.25 with a p-value of
2.98610
25 and 5.29610
25, respectively.
Discussion
Our main finding is that INDELS within the CD6 gene and the
STXBP6 gene are associated with EULAR response to TNFa
inhibitor treatment in patients with RA treated in routine care.
During the last decade biologic therapies have greatly improved
the treatment of patients with RA. Although highly effective,
concerns remain about the variable response rates to TNFa
inhibitors, the high costs of these drugs, and the risk of adverse
events associated with their use. Identification of genetic markers
associated with response to biologic therapies would allow tailored
treatments to individual patients with RA.
In this study of patients with RA we identified two genetic
biomarkers that are statistically associated with response to TNFa
inhibitor therapy. The CGEN-40002 amplicon is significantly
associated with EULAR good response versus EULAR no
response and EULAR good response versus EULAR moderate/
no response. The CGEN-40002 amplicon represents an insertion
within the CD6 gene on chromosome 11. The variation can be
found in version 130 of dbSNP, entry rs55799216. The genomic
location of the insertion is at position 60,542,552 on chromosome
11 (NCBI build 36), the sequence alignment of the two alleles is:
TCGCTCAAGGGGAAAAGGAGAAAGGAAGGG- - - - - - - - - -
--------- T A A A A G A A G A
TCGCTCAAGGGGAAAAGGAGAAAGGAAGGGGAAAAGGAGAAAG
GAAGGGTAAAAGAAGA
The inserted segment in the long allele is a copy of the
preceding 19 bp of the short allele. The variation is located in the
last intron of the gene, about 100 bp downstream of the end of the
preceding exon. This exon is alternative according to RNA
evidence, and there is also RNA evidence of intron retention for
this intron, both in human and in chimpanzee. Noteworthy, both
the human expressed sequence tags (ESTs) that cross this exon-
intron junction contain the 19 bp insertion. The 19 bp variation
may alter the splicing of the CD6 gene. CD6 is a cell surface
receptor which belongs to the scavenger receptor cysteine-rich
(SRCR) protein superfamily (SRCRSF) and is expressed primarily
on thymocytes and lymphocytes [31,32]. CD6 is considered to
play an important role in lymphocyte development and activation
through its binding to the activated leukocyte cell adhesion
molecule ALCAM/CD166. Interaction between CD6 and
ALCAM is crucial for proper immunological synapse maturation
and T cell proliferative responses [32]. A recent study suggested
that the CD6-ALCAM interaction activates the three mitogen-
activated protein kinase (MAPK) cascades which are suggested to
influence apoptosis of lymphocytes [33]. Interesting, genetic
variants within the MAPK genes are also suggested to influence
response to TNFa inhibitors in patients with RA [34,35].
The CGEN-40003 amplicon is significantly associated with
EULAR good response compared to EULAR no response. This
variation is an insertion with 7 alleles of varying lengths, and we
found that patients with the longest CGEN-40003 alleles were
more often classified as non- and moderate responders. The
CGEN-40003 amplicon represents a 2 bp short repeat within the
STXBP6 gene (syntaxin binding protein 6) on chromosome 14.
The variation lies within a very long intron, approximately
10 Kbp away from the closest exon. This microsatellite is
represented in dbSNP version 130 by several entries, for example
rs10630160, rs34132743, rs35668825. The reference genome
contains 17 TG repeats in positions 24,503,694-24,503,728, and
dbSNP describes alleles with 1–9 additional TG repeats. Adjacent
to the variation is a possible transcription binding site for
Peroxisome proliferator-activated receptor gamma (PPARG),
Table 4. Possible tests imposing a 10% genotype group size
condition in the 156 patients with either EULAR good
response or no response.
Possible tests Positive n (%) Negative n (%)
#1 Both alleles#271 80 (51%) 76 (49%)
# 2 Both alleles#280 86 (55%) 70 (45%)
# 3 Both alleles#284 107 (69%) 49 (31%)
# 4 One allele#271 139 (89%) 17 (11%)
# 5 Both alleles=271 79 (51%) 77 (49%)
# 6 One allele=271 139 (89%) 17 (11%)
# 7 One allele=284 24 (15%) 132 (85%)
# 8 One allele=288 45 (29%) 111 (71%)
doi:10.1371/journal.pone.0038539.t004
Table 5. Association between genotype and EULAR good response versus EULAR moderate response/no response.
Good EULAR
response (n=68)
Moderate/no response
(n=167)
Significance
threshold*** p-value
Odds
Ratio
CGEN-40002
Allele 512
negative 37 141 8.251610
25 3.336610
26 4.54*
Allele 512
positive 31 26
*Odds ratio for EULAR good response being 512 positive,
***after correction for dependency.
doi:10.1371/journal.pone.0038539.t005
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Evolutionary and Sequence Pattern Extraction through Reduced
Representations (ESPERR) score suggesting a potential functional
element in the genome [36]. The variation may have a direct effect
on the transcription of the STXBP6 gene or be correlated with
another variation in the region. STXBP6 is not a known RA
susceptibility gene or biomarker of response to TNFa inhibitors in
patients with RA but in a previous microarray study of patients
with RA treated with TNFa inhibitors, STXBP6 was differentially
expressed in responders compared to non responders [37].
STXBP6 is a syntaxin binding protein that binds to components
of the SNARE complex which inhibits membrane fusions
including phagocytosis [38]. Interestingly, a combined GWAS
and replication study has recently identified 4 loci within
STXBP6, ITGA4, MLZE and the MHC region associated with
monocyte counts in a cohort of 14,792 Japanese individuals [39].
STXBP6 is suggested to play a role in the immune response by
altering the ability of phagocytosis and antigen presentation of
monocytes and macrophages [39].
In our primary analysis, we tested the allele frequency in
patients with good EULAR response versus no EULAR response.
Our basic assumption was that for a biomarker which is correlated
to response there should be two distinct distributions of response
for the two genotypic groups. The moderate responders are likely
to be in the middle with contributions from both genotypic groups.
Therefore adding the moderate responders to either the good or
the non-responders was likely to reduce the p-value. On the other
hand adding the 81 patients with moderate EULAR response
increased the size of the population tested, making it possible for
less extreme distributions to reach significance. When patients with
moderate response were added, only CGEN-40002 was associated
with EULAR good response versus moderate/no EULAR
response. The CGEN-40003 amplicon was not associated with
EULAR response when patients with moderate EULAR response
were added to patients with either good or no response. However,
the genotypic distributions of patients with moderate response
were in between two extreme groups suggesting a quantitative
response effect of this gene.
Some strengths of our study are the genetically homogenous
and well-characterized cohort of Danish patients with RA treated
with TNFa inhibitors in routine care. Clinical data were collected
prospectively and independently of the present study in the
DANBIO registry, which has high data completeness and
coverage (.90%) [26]. One may argue that the population
heterogeneity with regard to disease duration, HAQ, and number
of previous DMARDs is a limitation of the study since long disease
duration and severe joint destruction may influence treatment
response and the assessment of clinical response. However,
heterogeneity also increases the external validity of the findings.
In recent years, candidate gene studies and GWASs have
successfully identified RA susceptibility genes. Similarly, several
genetic loci with suggestive association with response to TNFa
inhibitors have been identified, but only few have been replicated
in independent cohorts. This inconsistency may be influenced by
several factors including small sample size, small effect size of the
identified loci, allele frequency, heterogeneity with regard to
baseline characteristics, and differences in outcome measurements,
disease severity and TNFa inhibitor therapy. Lack of statistical
power remains one of the great challenges in pharmacogenetic
studies [40–42]. Small sample size can provide incorrect
estimation of effect size and small sample size of an initial study
might also explain the lack of replication in independent cohorts
[21,42–43]. In our study, the sample size of 237 patients does not
allow for the significance to be incontestable. Therefore, the
findings need to be validated in other populations of patients with
RA treated with TNFa inhibitors. Different classes of TNF
inhibitors (TNF-soluble receptors and neutralizing anti-TNF
antibodies) may not act through shared biological pathways which
warrant studies to be restricting to only one drug class or even to a
single drug [42]. Our study was not designed to perform sub-
analyses on patients stratified according to TNFa inhibitor drugs,
but this would be an interesting approach in a validation study.
The majority of the currently practiced association studies
utilize SNP based technologies for the genotyping process. Such
methods, which genotype numerous SNPs, usually require a large
sample collection in order to achieve statistically significant results.
However, it might be difficult to achieve significant results when
using a relatively small sample set. Such difficulty can be resolved
by genotyping a relatively small number of carefully selected
genetic variations rather than using the genome-wide approach
Figure 1. Allele distribution of the CGEN-40003 amplicon according to EULAR response. The Y-axis indicates percentage of patients. The
X-axis indicates EULAR response (good, moderate, none). The colored boxes indicate the size (base pair) of the longest allele.
doi:10.1371/journal.pone.0038539.g001
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studies. Yet, an advantage of using INDELS is that, since they
represent greater structural variation than SNPs, they are more
likely to be the actual genetic basis of phenotypic differences
between individuals. Moreover, in some cases utilizing multi-allelic
INDELS (such as microsatellites) might be more useful than SNPs
[46]. In the present study, we did only test common INDELS with
a length of maximum 500 bp. Rare INDELS .500 kb and other
large genetic variations such as copy number variations, which are
likely to be more deleterious, were not tested.
In conclusion, we identified genetic variations within the CD6
and the STXBP6 genes associated with response to TNFa
inhibitors in a cohort of homogeneous Danish patients with RA.
Future, prospective studies including a larger number of patients
with RA are needed to achieve a greater understanding of
treatment failure and to evaluate if genetic variations within the
CD6 and the STXBP6 can provide useful information regarding
treatment response and contribute to a more personalized
treatment strategy in the future.
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Table S1 Tested amplicons. Protocol: sequencing or frag-
ment analysis; #alleles: the number of alleles for each INDEL;
Ntest: number of tests that were performed for each INDEL when
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fraction of samples that were genotyped successfully; Hw (Hardy-
Weinberg equilibrium): p-value of a chi-square test comparing the
homozygotes and heterozygotes distribution. The value in the
table is the minimal value for all subdivisions of the alleles into two
groups; Min p-value: p-value of a Fisher’s exact test comparing
good responders to non-responders. The value in the table is the
minimal value of all tests done for each INDEL.
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